[ad_1]
New data suggests that people whose immune systems have responded strongly to the MMR vaccine may be less likely to be severely infected with the emerging coronavirus. The MMR2 vaccine, manufactured by Merck and licensed in 1979, stimulates the immune system to produce antibodies.
On Friday (November 20, 2020), researchers reported in the journal MBIO that it was found that among 50 Covid-19 patients under the age of 42 who were vaccinated with the MMR2 vaccine as children, the higher the levels of antibodies. called EGJs produced by the vaccine and directed against the mumps virus in particular, if its symptoms are less severe.
And Covid-19 was asymptomatic in people who had the highest level of antibodies to mumps.
More research is needed to show that the vaccine prevents acute COVID-19 infection. However, Jeffrey Gold, who participated in the study, said in a statement that the new findings “could explain why the incidence of children with Covid-19 is significantly lower than that of adults, as well as a much lower mortality rate. “.
Read also: Minister decides: is the Corona vaccine voluntary or mandatory in Germany?
He said: “Most children receive the first vaccination against measles, mumps and rubella at the age of 12-15 months, while the second is vaccinated from the age of 4-6.”
Db / ks (Reuters)
-
The decline in the immune response is the biggest obstacle to developing a Corona vaccine
‘Fast fade’
Initial studies conducted in China, Germany, Britain, and other countries concluded that patients infected with the emerging coronavirus develop protective antivirus bodies as part of the body’s immune system, but these bodies appear to remain effective for only a few months. Daniel Altman, professor of immunology at Imperial College London, said that “their effect (self-developed protective bodies) often diminishes rapidly.”
-
The decline in the immune response is the biggest obstacle to developing a Corona vaccine
Two options for vaccine developers
Experts say the rapid weakening of immunity raises serious problems for vaccine developers and public health authorities, as well as those trying to spread these vaccines to protect their people from future epidemics. “For vaccines to be truly effective, there are two options: either the need to develop more robust, long-term protection … or the vaccine should be obtained regularly,” said Stephen Griffin, assistant professor of medicine at the university. of Leeds.
-
The decline in the immune response is the biggest obstacle to developing a Corona vaccine
World race
More than 100 companies and research groups are trying to develop vaccines, of which at least 17 are currently being tested on humans. The American company Moderna announced on Tuesday (July 15, 2020) that clinical trials will enter the final phase on July 27. Moderna is therefore the first company to reach this stage. Russia announced that it has completed the first clinical trials of an experimental human-tested vaccine, to be completed by the end of July.
-
The decline in the immune response is the biggest obstacle to developing a Corona vaccine
Two doses are “better” than one
In preclinical studies in pigs to monitor the effect of a vaccine developed by the pharmaceutical company (AstraZeneca) for the treatment of Covid-19, known as (AZD 1222), it was found that two doses of the vaccine contributed to the better antibody response of a dose. However, so far, there are no recorded data from any human vaccine trials to prove whether an immune response to the antibody will be strong or lasting enough.
-
The decline in the immune response is the biggest obstacle to developing a Corona vaccine
Time pressure
Geoffrey Arnold, visiting professor of microbiology at the University of Oxford in Britain and former expert at Sanofi Pasteur, said the very rapid development and testing of potential vaccines against the Corona virus has been underway for only six months, the which isn’t long enough to show how long vaccines could deliver. Experts expect it will take 12-18 months to produce a safe and effective vaccine from the start of development.
-
The decline in the immune response is the biggest obstacle to developing a Corona vaccine
Booster doses
One approach, Griffin-Arnold said, could be that when these vaccines are developed, authorities should consider taking booster doses for millions of people at regular intervals or even combining two or more vaccines for each person to get the best possible protection. However, this can present a major practical challenge. “Giving the whole world one dose of the vaccine is one thing … and giving them multiple doses is another thing entirely,” he said.
.
[ad_2]
Source link
